Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ARIA

Ariad Pharmaceuticals (ARIA) Stock Price, News & Analysis

Ariad Pharmaceuticals logo

About Ariad Pharmaceuticals Stock (NASDAQ:ARIA)

Advanced Chart

Key Stats

Today's Range
$23.99
$23.99
50-Day Range
N/A
52-Week Range
$4.67
$23.99
Volume
N/A
Average Volume
15.70 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Receive ARIA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ariad Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARIA Stock News Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
Affimed Appoints Shawn Leland As New CEO
See More Headlines

ARIA Stock Analysis - Frequently Asked Questions

Ariad Pharmaceuticals Inc (NASDAQ:ARIA) issued its earnings results on Thursday, July, 28th. The pharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of ($0.11) by $0.70. The firm's revenue for the quarter was up 133.0% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ariad Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Meta Platforms (META), Bristol-Myers Squibb (BMY), Twitter (TWTR), ACADIA Pharmaceuticals (ACAD), Ford Motor (F) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
7/28/2016
Today
5/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ARIA
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:ARIA) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners